title: A successful renal transplantation for renal failure after dasatinib-induced thrombotic thrombocytopenic purpura in a patient with imatinib-resistant chronic myelogenous leukaemia on nilotinib.
abstract: Second-generation tyrosine kinase inhibitors (TKI2) often induce molecular remission, and prolonged survival with a better tolerance in imatinib-resistant chronic myelogenous leukaemia (CML) patients. We report the case of a CML in first chronic phase who was diagnosed in August 2003 in a young 24 year-old Caucasian woman. Our patient received first imatinib and then dasatinib and nilotinib. Imatinib was well tolerated and she developed TTP/HUS on dasatinib without documented evolution of CML and finally obtained MR5.0 with nilotinib and without any side effect. This case also illustrates the absence of cross-resistance and side-effects between the different TKIs and the feasibility of kidney transplantation associated with a nilotinib treatment of CML allowing a continuing MR5.0 and no further side effects.
authors.affiliation: CHU Besançon, Service d'Hématologie, Besançon, France.
authors.forename: Suella
authors.initials: S
authors.lastname: Martino
authors.affiliation: CHU Besançon, Service d'Hématologie, Besançon, France ; Université de Franche-Comté, IFR 133, Besançon, France.
authors.forename: Etienne
authors.initials: E
authors.lastname: Daguindau
authors.affiliation: Etablissement Français du sang Bourgogne Franche-Comté (EFS B/FC), Laboratoire d'onco-hématologie moléculaire, 25020 Besançon cedex, France ; Inserm UMR1098, Besançon, France, 4 CHU Besançon, service de Néphrologie, Besançon, France ; Fi-LMC, Poitiers, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Ferrand
authors.affiliation: Inserm UMR1098, Besançon, France, 4 CHU Besançon, service de Néphrologie, Besançon, France ; Université de Franche-Comté, IFR 133, Besançon, France.
authors.forename: Jamal
authors.initials: J
authors.lastname: Bamoulid
authors.affiliation: Laboratoire Biologie moléculaire (Hématologie), CHU Lyon Sud 69495 Pierre Bénite, France ; Fi-LMC, Poitiers, France.
authors.forename: Sandrine
authors.initials: S
authors.lastname: Hayette
authors.affiliation: Service d'Hématologie clinique 1G, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite, France ; Fi-LMC, Poitiers, France.
authors.forename: F-E
authors.initials: FE
authors.lastname: Nicolini
authors.affiliation: CHU Besançon, service de Réanimation, Besançon, France.
authors.forename: G
authors.initials: G
authors.lastname: Capellier
authors.affiliation: CHU Besançon, Service d'Hématologie, Besançon, France ; Inserm UMR1098, Besançon, France, 4 CHU Besançon, service de Néphrologie, Besançon, France ; Université de Franche-Comté, IFR 133, Besançon, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Deconinck
authors.affiliation: CHU Besançon, Service d'Hématologie, Besançon, France ; Fi-LMC, Poitiers, France.
authors.forename: Fabrice
authors.initials: F
authors.lastname: Larosa
keywords: CML; Dasatinib; Kidney transplantation; Nilotinib; TTP/HUS